The disclosure provides novel antigen-binding proteins that bind STEAP1 and methods of use.

The present invention relates to the field of immunology, in particular, to the field of modulation of immune responses, in particular, suppression of immune responses and/or induction of tolerance. It provides a tregitope (regulatory T cell activating epitope) carrying polypeptide based on sequences derived from the Fc part of human IgG, wherein said TCP comprises at least one tregitope heterologous to human IgG that is located within at least one of three specific sequence frames. The invention provides such polypeptides for multiple purposes, e.g., in monomeric or dimeric form, wherein both are optionally be linked to an agent, e.g., to which an immune response is to be modulated or suppressed, or co-administered to such an agent, or for use as a stand-alone therapeutic. Nucleic acids encoding the TCP of the invention, pharmaceutic compositions and uses of said TCP are also provided.

The present invention provides compositions of CD 180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.

The present invention relates to a Varicella zoster virus fusion protein and an immunogenic composition comprising same and, more specifically, to a fusion protein comprising the glycoprotein E (gE) of Varicella zoster virus (VZV) and a constant region of an immunoglobulin molecule, and an immunogenic composition comprising same. The present invention not only remarkably increases a Varicella zoster virus-specific cell-mediated immune response, but also exhibits the effect of rapidly and potently inducing an immune response and sustaining the immune response for a long period of time, compared to preexisting vaccines, thereby can be usefully used to prevent Varicella zoster-related diseases.

The disclosure relates to immunoglobulin variants that are useful for the design of vaccinations against a variety of athogens and their method of production and use. In some aspects, the immunoglobulin variants are variants of IgG, for example, the 6D8 antibody.

A fusion protein for cancer treatment and a use thereof is disclosed. The fusion protein for preventing or treating cancer of the present invention includes a fusion polypeptide including: an antibody or fragment thereof binding to a tumor-associated antigen; a linker; and a NK cell-inducing protein of CXCL16, wherein a co-administration of the fusion polypeptide along with the NK cells, an immunocyte therapeutic agent, greatly increases an influx of the NK cells into cancer expressing a certain antigen, thereby having a remarkable effect on preventing or treating cancer.

A fusion protein comprises a first nanocage monomer subunit of a nanocage monomer; and a bioactive moiety linked to the first nanocage monomer subunit; wherein the fusion protein self-assembles with a protein comprising a second nanocage monomer subunit to form a nanocage monomer.

Compositions and methods for the prevention and/or treatment of a viral infection, in particular of the Coronaviridae family.

Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having an open reading frame encoding at least one varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.

Disclosed herein are methods of forming compounds and exemplary stable compounds in the nature of a conjugated compound at refrigerated or room temperature, which in some embodiments comprises an antigen and virus particle mixed in a conjugation reaction to form a conjugate mixture, such that the conditions and steps of forming these products allow for use of the conjugate mixture as a vaccine, including but not limited to use as a vaccine against various pathogens including for treatment of diseases caused by novel coronaviruses (including SARS-COV 2).